A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer. A small early-phase trial found that incorporating the oncolytic virus talimogene laherparepvec T-VEC into neoadjuvant chemotherapy was feasible and tolerable for patients with triple-negative breast cancer TNBC. The regimen also showed promising efficacy in this small cohort of patients. The study included 9 patients 10 consented, but 1 then withdrew consent prior to treatment with TNBC. They were treated with paclitaxel, given weekly for 12 weeks, along with 5 doses of T-VEC at several dose levels given at weeks 1, 4, 6, 8, and 10 of the paclitaxel therapy.
Viroimmunotherapy for breast cancer: promises, problems and future directions
Viroimmunotherapy for breast cancer: promises, problems and future directions | Cancer Gene Therapy
Triple-negative breast cancer TNBC is a difficult-to-treat disease with high rates of local recurrence, distant metastasis, and poor overall survival with existing therapies. Thus, there is an unmet medical need to develop new treatment regimen s for TNBC patients. In vivo in the 4T1 syngeneic TNBC model, it significantly reduced primary tumor burden and metastasis, both at early and late stages of tumor development. Breast cancer is one of the most prevalent malignancies and the second most common cause of death among women in the United States 1. Tumor recurrence, metastasis to other vital organs, and high heterogeneity are considered hallmarks of TNBC variants 3. Since TNBC does not express hormone receptors, the current treatment for TNBC mainly relies on surgery and chemotherapy; targeted therapy, such as hormone-based treatments or HER2 antagonists, is not a treatment option 4. Moreover, TNBC initially responds well but often develops resistance against chemotherapy 5 , which underscores the need for developing novel therapeutic modalities that efficiently cure TNBC in patients.
Adding an Oncolytic Virus to Neoadjuvant Chemo for Triple-Negative Breast Cancer
Cancer is the result of normal cellular functions going wildly awry on a genetic level. That fact has been known for some time, but increasing evidence is showing that the human microbiome, the diverse population of microorganisms within every person, may play a key role in either setting the stage for cancer or even directly causing some forms of it. Robertson, PhD , and James C. Alwine, PhD , has identified, for the first time, an association between two microbial signatures and triple-negative breast cancer, the most aggressive form of the disease. The work was published by Banerjee et al in Scientific Reports.